Evidence map›Paper›PMID 35015172›Full record

ArticleInvestigational new drugs2022

Phenformin increases early hematopoietic progenitors in the Jak2

Antônio Bruno Alves-Silva, Bruna Alves Fenerich, Natasha Peixoto Fonseca, Jaqueline Cristina Fernandes, Juan Luiz Coelho-Silva, Diego Antonio Pereira-Martins, Thiago Mantello Bianco, Priscila Santos Scheucher, Eduardo Magalhães Rego, Fernando Chahud and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Antônio Bruno Alves-SilvaDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
Bruna Alves FenerichDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
Natasha Peixoto FonsecaDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
Jaqueline Cristina FernandesDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
Juan Luiz Coelho-SilvaDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
Diego Antonio Pereira-MartinsCenter for Cell Based Therapy, São Paulo Research Foundation, Ribeirão Preto, Brazil.
Thiago Mantello BiancoDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
Priscila Santos ScheucherDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
Eduardo Magalhães RegoCenter for Cell Based Therapy, São Paulo Research Foundation, Ribeirão Preto, Brazil.
Fernando ChahudDepartament of Pathology and Legal Medicine, University of São Paulo at Ribeirão Preto Medical School, Ribeirão Preto, Brazil.
João Agostinho Machado-NetoDepartment of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Lorena Lôbo Figueiredo-PontesDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil.
Fabiola TrainaDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of Sao Paulo, Ribeirão Preto, Brazil. ftraina@fmrp.usp.br.
Universidade de São Paulo · BRFundação de Amparo à Pesquisa do Estado de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyeloproliferative neoplasms (MPN) are disorders characterized by an alteration at the hematopoietic stem cell (HSC) level, where the JAK2 mutation is the most common genetic alteration found in classic MPN (polycythemia vera, essential thrombocythemia, and primary myelofibrosis). We and others previously demonstrated that metformin reduced splenomegaly and platelets counts in peripheral blood in JAK2

aimsWe herein aimed to investigate the effects of phenformin in MPN disease burden and stem cell function in Jak2

resultsIn vitro phenformin treatment reduced cell viability and increased apoptosis in SET2 JAK2

conclusionsPhenformin increased the percentages of LSK, MP, and MPP populations, but did not reduce disease burden in Jak2

Indexed as

Myeloproliferative DisordersPolycythemia VeraAnimalsBone MarrowDisease Models, AnimalHumansJanus Kinase 2MiceMutationPhenforminJAK2 protein, humanJanus Kinase 2PhenforminBiguanideJAK2Murine modelMyeloproliferative neoplasmsPhenforminPolycythemia vera

Identifiers

PMID35015172
OpenAlexW4206000379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.